Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.83 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.53 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250527 | 0.92 | EPHX2 (0.84) | EPHX2CRACR2ATEKMEN1TSHR | |
| SCHEMBL4245798 | 0.92 | EPHX2 (0.91) | EPHX2CRACR2ATEKMEN1TSHR | |
| SCHEMBL4248610 | 0.91 | EPHX2 (0.83) | EPHX2CRACR2ATEKBRAFCSF1R | |
| SCHEMBL4248491 | 0.91 | EPHX2 (1.00) | EPHX2CRACR2ATEKABL1BCR | |
| SCHEMBL4248369 | 0.90 | EPHX2 (0.82) | EPHX2CRACR2ATEKMEN1KMT2A | |
| SCHEMBL4248906 | 0.90 | EPHX2 (0.82) | EPHX2CRACR2ATEKKMT2ABRAF | |
| SCHEMBL4250539 | 0.90 | EPHX2 (0.82) | EPHX2CRACR2ATEKKMT2ACSF1R | |
| SCHEMBL4250841 | 0.90 | EPHX2 (0.82) | EPHX2CRACR2ATEKMEN1TSHR | |
| SCHEMBL4252693 | 0.90 | EPHX2 (0.82) | EPHX2CRACR2ATEKABL1 | |
| SCHEMBL14507836 | 0.90 | EPHX2 (0.80) | EPHX2CRACR2ATEKMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | EPHX2 2/4885CRACR2A 3167/4885TEK 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.